Free tool
FAERS Monitor: Rayaldee
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208010 or its brand name (Rayaldee, Calcifediol). Reports on generic versions are filed under their own applications.
Reports
2,547
Serious
2,435
96% of reports
Hospitalization
1,307
Death reported
384
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death219
- off label use141
- drug interaction131
- acute kidney injury127
- anaemia78
- nausea76
- dyspnoea74
- pneumonia70
- pyrexia70
- covid-1964
- hypotension63
- diarrhoea62
- vomiting60
- drug ineffective59
- somnolence59
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 5 |
| 2010 | 12 |
| 2011 | 2 |
| 2012 | 10 |
| 2013 | 7 |
| 2014 | 9 |
| 2015 | 11 |
| 2016 | 15 |
| 2017 | 40 |
| 2018 | 79 |
| 2019 | 122 |
| 2020 | 158 |
| 2021 | 166 |
| 2022 | 267 |
| 2023 | 392 |
| 2024 | 494 |
| 2025 | 358 |
| 2026 | 384 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,612 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 127 | 6.9 | 5.8 | 634 |
| drug interactionSignal | 131 | 6.8 | 5.8 | 650 |
| anaemiaSignal | 78 | 3.4 | 2.7 | 129 |
| covid-19Signal | 64 | 3.0 | 2.4 | 85 |
| hypotensionSignal | 63 | 2.6 | 2.0 | 61 |
| somnolenceSignal | 59 | 2.4 | 1.9 | 48 |
| deathSignal | 219 | 2.1 | 1.8 | 130 |
| pneumonia | 70 | 1.8 | 1.4 | 24 |
| pyrexia | 70 | 1.7 | 1.3 | 18 |
| off label use | 141 | 1.3 | 1.1 | 12 |
| dyspnoea | 74 | 1.1 | 0.9 | 0 |
| vomiting | 60 | 1.1 | 0.8 | 0 |
| diarrhoea | 62 | 0.8 | 0.6 | 3 |
| nausea | 76 | 0.8 | 0.6 | 4 |
| drug ineffective | 59 | 0.4 | 0.3 | 67 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.